Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

Clinical trial NCT06504368 · RECRUITING

Trial details

NCT number: NCT06504368
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors, Adult

Start date: 2024-05-29
Primary completion: 2026-06-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.